Avi Biopharma, Inc. (AVII) Income Statement

Click line-items for a historical chart and %

Statements Of Operations
Revenues from license fees, grants and research contracts
Operating expenses:
Research and development	34.35M
General and administrative	22.18M
Acquired in-process research and development
Operating loss	-56.53M
Other non-operating (loss) income:
Interest (expense) income and other, net
(Increase) decrease on warrant valuation
Realized gain on sale of short-term securities-available-for-sale
Write-down of short-term securities-available-for-sale
Total other non operating income	-209K
Net income (loss) and comprehensive income (loss)	-56.74M
Net income (loss) per share - basic
Net income (loss) per share - diluted
Weighted average number of common shares outstanding for computing basic income (loss) per share (in thousands)
Weighted average number of common shares outstanding for computing diluted income (loss) per share (in thousands)

Entities mentioned with AVII